NYSE$BLCO
Bausch + Lomb Corp · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Announced third-quarter 2022 results, with revenue decline of 1% but organic revenues grew 5%, driven by growth across all segments, and a GAAP net loss of $18 million.
Bausch + Lomb reported a slight decrease in revenue, declining by 1% to $942 million, but experienced organic revenue growth of 5% across all segments. The company faced a GAAP net loss of $18 million, while adjusted EBITDA stood at $187 million.
- Revenues of $942 Million
- GAAP Net Loss Attributable to Bausch + Lomb Corporation of $18 Million
- Adjusted EBITDA (non-GAAP) of $187 Million
- Third-Quarter Reported Revenues Declined 1%, and Organic Revenues Grew 5%, Driven by Growth Across All Segments
Headline financials
Revenue & EPS history
Bausch + Lomb · Revenue · Quarterly
$942M
Revenue by segment
Bausch + Lomb · $942M total across 3 segments · Q3 2022
- Vision Care$598M-1.2%63.5%
- Surgical$172M-0.6%18.3%
- Pharmaceuticals$172M+42.1%18.3%
Forward guidance
Bausch + Lomb revised its revenue and Adjusted EBITDA guidance for the full year of 2022, due to the negative impact of foreign exchange. Adjusted EBITDA guidance also reflects a slower than expected ramp-up in manufacturing yield of Bausch + Lomb INFUSE®/ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.
Tailwinds
- Full-year revenue range of $3.70 – $3.75 billion, reaffirming 4-5% organic growth
Headwinds
- Full-year Adjusted EBITDA range of $715 – $755 million
- Due to the negative impact of foreign exchange
- Adjusted EBITDA guidance also reflects a slower than expected ramp-up in manufacturing yield of Bausch + Lomb INFUSE®/ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-1.0%
Avg return
Earnings day
-1.8%
Avg return
5 days after
-1.0%
Avg return
30 days after
43%
9 / 21 earnings
Positive
+18.7%
Q4 2023
Best reaction
-15.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | +2.9% | -1.0% | |
| Q4 2025 | +0.2% | +1.5% | -11.3% | |
| Q3 2025 | +2.1% | +0.3% | +6.5% | |
| Q1 2025 | -15.7% | -17.1% | -16.4% | |
| Q4 2024 | -0.3% | -3.3% | -4.8% | |
| Q3 2024 | -2.3% | -4.3% | -4.5% | |
| Q2 2024 | -0.1% | -8.7% | -2.6% | |
| Q1 2024 | -4.7% | -0.7% | +5.5% | |
| Q4 2023 | +18.7% | +15.7% | +10.8% | |
| Q3 2023 | +4.6% | +2.9% | -4.3% | |
| Q2 2023 | -2.5% | -3.4% | -7.2% | |
| Q1 2023 | +0.1% | +4.6% | +4.4% | |
| Q4 2020 | +0.4% | -3.7% | -14.1% | |
| Q4 2022 | +0.4% | -3.7% | -14.1% | |
| Q3 2022 | -4.9% | +5.6% | +7.9% | |
| Q3 2021 | -4.9% | +5.6% | +7.9% | |
| Q2 2022 | +4.7% | +6.3% | +1.2% | |
| Q2 2021 | +4.7% | +6.3% | +1.2% | |
| Q1 2022 | -6.8% | -14.6% | +5.0% | |
| Q4 2021 | -6.8% | -14.6% | +5.0% | |
| Q1 2021 | -6.8% | -14.6% | +5.0% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro